ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМПymj-1181Research ArticleОБМЕН ОПЫТОМEXPERIENCE EXCHANGEОпыт использования индакатерола с позиции кардиоваскулярной безопасностиExperience of using the indacaterol from the position of cardiovascular safetyМельникА. В.MelnikA. V.

Мельник Алексей Владимирович – зав. отд., врач пульмонолог ГБУЗ НСО «ГКБ №25».

Новосибирск

a.v.melnik@list.ruЛогвиненкоН. И.LogvinenkoN. I.

Логвиненко Надежда Ивановна – д.м.н., проф.

nadejda-logvinenko@yandex.ruАстраковС. В.AstrakovS. V.

Астраков Сергей Викторович – д.м.н., проф. НГМУ МЗ РФ, гл. врач ГКБ № 25

astr_sv@mail.ruГБУЗ НСО «ГКБ №25»РоссияНовосибирский ГМУ МЗ РФРоссияНГМУ МЗ РФ; ГКБ № 25Россия2017270820250498100Copyright © Мельник А.В., Логвиненко Н.И., Астраков С.В., 20252025Мельник А.В., Логвиненко Н.И., Астраков С.В.Melnik A.V., Logvinenko N.I., Astrakov S.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/1181

Проведено изучение клинической эффективности терапии ингалятором онбрез бризхалер и её влияние на основные клинические симптомы, качество жизни (оценочный тест CAT), показатели функции внешнего дыхания, ЧСС, интервал QTc и концентрацию калия в крови у госпитализированных больных ХОБЛ. На основании полученных данных можно сделать вывод, что индакатерол, применяемый один раз в сутки в дозе 150 мкг, является эффективным лечением для больных ХОБЛ: обеспечивает значительную бронходилатацию, уменьшает клинические проявления, улучшает качество жизни пациентов и имеет благоприятный профиль кардиоваскулярной безопасности.

Clinical efficacy of inhalation therapy by Onbrez®Breezhaler® and examination of the effect on the leading clinical symptoms, quality of life (COPD Assessment Test), lung function, heart rate, QTc interval and the potassium level in blood in hospital patients with COPD were under study. Based on the found evidence we can conclude that once daily administration of indacaterol at a dose of 150 mcg is an effective treatment for patients with COPD. It provides significant bronchodilation, reduces clinical manifestations, improves the quality of life of patients and has a favorable cardiovascular safety profile.

ХОБЛлечениеиндакатеролонбрез бризхалерCOPDtreatmentindacaterolOnbrez®Breezhaler®ReferencesОсобенности ведения пациентов с хронической обструктивной болезнью легких в сочетании с сердечно-сосудистыми заболеваниями: методические рекомендации для врачей / Е.Д. Баздырев [и др.]. – Кемерово, 2012. – 55 С.Features of management of patients with chronic obstructive pulmonary disease in combination with cardiovascular diseases: methodical recommendations for doctors / E.D. Bazdyrev [et al.]. – Kemerovo, 2012. – 55 p.Особенности кардиальной патологии у больных бронхиальной астмой и ХОБЛ / Е.В. Заикина, А.А. Низов [и др.] // Сборник трудов конгресса. XXIII Национальный конгресс по болезням органов дыхания. – 2013. – C. 21.Features of cardiac pathology in patients with bronchial asthma and COPD / E.V. Zaikina, A.A. Nizov [et al.] // Proceedings of Congress. XXIII National Congress on Diseases of the Respiratory System. – 2013. – P. 21.Характер аритмий при болезнях органов дыхания / Н.Ш. Загиддулин, Ю.Ф. Сафина, Г.Р. Халимова, У.Р. Фархутдинов // Сборник трудов конгресса. XXII Национальный конгресс по болезням органов дыхания. – 2012. – С. 240.The nature of arrhythmias in diseases of the respiratory system / N.Sh. Zagiddulin, Yu.F. Safina, G.R. Khalimova, U.R. Farhutdinov // Proceedings of the Congress. XXII National Congress on Diseases of the Respiratory System. – 2012. – P. 240.Шугушев Х.Х. Наджелудочковые аритмии и ЭКГ высокого разрешения у больных хронической обструктивной болезнью легких на фоне бронхолитической терапии / Х.Х. Шугушев, М.В. Гурижева, В.М. Василенко // Российский кардиологический журнал. – 2010. – № 6 (86). – С. 40–44.Shugushev H.Kh. Supraventricular arrhythmias and high-resolution ECG in patients with chronic obstructive pulmonary disease on the background of bronchodilator therapy / X.H. Shugushev, M.V. Gurizheva, V.M. Vasilenko // Russian Cardiology Journal (Rus.). – 2010. – №6 (86). – P.40-44.Шугушев Х.Х. Влияние бронходилататоров на вариабельность ритма серца у больных хронической обструктивной болезнью легких / Х.Х. Шугушев, М.В. Гурижева, В.М. Василенко // Рациональная фармакотерапия в кардиологии. – 2007. – № 4. – С. 51–54.Shugushev H.Kh. Influence of bronchodilators on the heart rate variability in patients with chronic obstructive pulmonary disease / H.H. Shugushev, M.V. Gurizheva, V.M. Vasilenko // Rational Pharmacotherapy in Cardiology. 2007. № 4. – P. 51-54.Atsou K. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review / K. Atsou, C. Chouaid, G. Hejblum// BMC Medicine. – 2011. – Vol. 9. – Р.7.Atsou K. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review / K. Atsou, C. Chouaid, G. Hejblum// BMC Medicine. – 2011. – Vol. 9. – Р.7.Bronchodilatator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study / M. Wilchesky, P. Ernst, J.M. Brophy, R.W. Platt, S.Suissa // Chest. – 2012. – №142(2). – P. 298–304.Bronchodilatator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study / M. Wilchesky, P. Ernst, J.M. Brophy, R.W. Platt, S.Suissa // Chest. – 2012. – №142(2). – P. 298–304.Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study/ G. Feldman, T. Siler, N. Prasad [et al.] // BMC Pulm Med 2010; 10: 11.Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study/ G. Feldman, T. Siler, N. Prasad [et al.] // BMC Pulm Med 2010; 10: 11.Gulsvik A. Cardiac arrhythmias in patients with serious pulmonarydiseases /A. Gulsvik, V. Hansteen, E. Sivertssen // Scand J Respir Dis. 1978. – Vol. 59. – Р.154–159.Gulsvik A. Cardiac arrhythmias in patients with serious pulmonarydiseases /A. Gulsvik, V. Hansteen, E. Sivertssen // Scand J Respir Dis. 1978. – Vol. 59. – Р.154–159.INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD/ D.E. O’Donnell, R. Casaburi, W. Vincken [et al.] // Respir Med 2011; 105 (7): 1030–6.INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD/ D.E. O’Donnell, R. Casaburi, W. Vincken [et al.] // Respir Med 2011; 105 (7): 1030–6.INHANCE Study Investigators.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium/ J.F. Donohue, C. Fogarty, J. Lötvall [et al.] // Am J Respir Crit Care Med 2010; 182 (2): 155–62.INHANCE Study Investigators.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium/ J.F. Donohue, C. Fogarty, J. Lötvall [et al.] // Am J Respir Crit Care Med 2010; 182 (2): 155–62.INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison/O. Kornmann, R. Dahl, S. Centanni [et al.] //Eur. Respir J 2011; 37 (2): 273–9.INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison/O. Kornmann, R. Dahl, S. Centanni [et al.] //Eur. Respir J 2011; 37 (2): 273–9.On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD/R. Dahl, K.F. Chung, R. Buhl [et al.] // Thorax 2010; 65: 473–9.On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD/R. Dahl, K.F. Chung, R. Buhl [et al.] // Thorax 2010; 65: 473–9.Pauwels R.A. Burden and clinical features of chronic obstructive pulmonary disease (COPD) / R.A. Pauwels, K.F. Rabe // Lancet 2004; 364: 613–20.Pauwels R.A. Burden and clinical features of chronic obstructive pulmonary disease (COPD) / R.A. Pauwels, K.F. Rabe // Lancet 2004; 364: 613–20.Pulmonary function is a long_term predictor of mortality in the general population: 29-year follow_up of the Buffalo Health Study /H.J. Schunemann, J. Dorn, B.J. Grant [et al.] // Chest. – 2000. – Vol. 118. – P. 656-664.Pulmonary function is a long_term predictor of mortality in the general population: 29-year follow_up of the Buffalo Health Study /H.J. Schunemann, J. Dorn, B.J. Grant [et al.] // Chest. – 2000. – Vol. 118. – P. 656-664.Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study / P. Buch, J. Friberg, H. Scharling [et al.]. – 2003. – Vol. 21 (6). – P. 1012-1016.Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study / P. Buch, J. Friberg, H. Scharling [et al.]. – 2003. – Vol. 21 (6). – P. 1012-1016.Rennard S.I. Bronchodilator sin chronic obstructive pulmonary disease. In: Management of chronic obstructive pulmonary disease. Ed. N.M.Siafakas. Eur. Respir .Monograph 2006; 11: 266-80Rennard S.I. Bronchodilator sin chronic obstructive pulmonary disease. In: Management of chronic obstructive pulmonary disease. Ed. N.M.Siafakas. Eur. Respir .Monograph 2006; 11: 266-80Respiratory symptoms and long-term cardiovascular mortality / A. Frostad, V. Soyseth, T. Haldorsen [et al.] // Respir Med 2007: 101: 2289–96.Respiratory symptoms and long-term cardiovascular mortality / A. Frostad, V. Soyseth, T. Haldorsen [et al.] // Respir Med 2007: 101: 2289–96.Sin D.D. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature / D.D. Sin, L. Wu, S.F. Man// Chest. 2005. Vol. 127. Р. 1952–1959.Sin D.D. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature / D.D. Sin, L. Wu, S.F. Man// Chest. 2005. Vol. 127. Р. 1952–1959.World Health Organisation Website. Chronic Obstructive Pulmonary Disease http://www.who.int/respiratory/copd.World Health Organisation Website. Chronic Obstructive Pulmonary Disease http://www.who.int/respiratory/copd.World Health Organization. COPD predicted to be third leading cause of death in 2030. Available from: http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/. Accessed May 1, 2014.World Health Organization. COPD predicted to be third leading cause of death in 2030. Available from: http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/. Accessed May 1, 2014.

The authors declare that there are no conflicts of interest present.